合成与生物改善病情抗风湿药安全性:2016年EULAR类风湿关节炎管理建议系统文献综述
结合2013年综述证据,生物改善病情抗风湿药较传统合成改善病情抗风湿药严重感染风险升高(aHR 1.1–1.8),结核风险升高(aHR 2.7–12.5),但带状疱疹感染风险未增加;总体恶性肿瘤、淋巴瘤和非黑色素瘤皮肤癌风险未增加,黑色素瘤风险可能轻度升高(aHR 1.5)。
要点
- 生物改善病情抗风湿药较传统合成改善病情抗风湿药严重感染风险升高(aHR 1.1–1.8),不同生物制剂间无差异。
- 生物改善病情抗风湿药结核风险升高(aHR 2.7–12.5),但带状疱疹感染风险未增加。
- 总体恶性肿瘤、淋巴瘤和非黑色素瘤皮肤癌风险未增加,黑色素瘤风险可能轻度升高(aHR 1.5)。
核心结论
- 生物改善病情抗风湿药(含TNFi和非TNFi)治疗类风湿关节炎的安全性模式与已知一致。
研究设计与样本
- 结合2013年系统文献综述证据(基于15项研究,其中7项低偏倚风险)进行综合分析。
主要发现
- 生物改善病情抗风湿药较传统合成改善病情抗风湿药严重感染风险升高(aHR 1.1–1.8),不同生物制剂间无差异。
- 生物改善病情抗风湿药结核风险升高(aHR 2.7–12.5),带状疱疹感染风险未增加。
- 生物改善病情抗风湿药总体恶性肿瘤、淋巴瘤和非黑色素瘤皮肤癌风险未增加,黑色素瘤风险可能轻度升高(aHR 1.5)。
临床怎么用
- 临床使用生物改善病情抗风湿药时应关注严重感染和结核风险,治疗前进行结核筛查。
- 对黑色素瘤风险可能轻度升高保持警惕,但总体恶性肿瘤风险未增加。
局限性
- 纳入研究异质性大,未进行meta分析。
- 部分安全性结局研究数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included. Risk of bias was assessed with the Hayden's tool. RESULTS: Twenty-six observational studies addressing diverse safety outcomes of therapy with bDMARDs met eligibility criteria (15 on serious infections, 4 on malignancies). Substantial heterogeneity precluded meta-analysis. Together with the evidence from the 2013 SLR, based on 15 studies, 7 at low risk of bias, patients on bDMARDs compared with patients on conventional sDMARDs had a higher risk of serious infections (adjusted HR (aHR) 1.1 to 1.8)-without differences across bDMARDs-a higher risk of tuberculosis (aHR 2.7 to 12.5), but no increased risk of infection by herpes zoster. Patients on bDMARDs did not have an increased risk of malignancies in general, lymphoma or non-melanoma skin cancer, but the risk of melanoma may be slightly increased (aHR 1.5). CONCLUSIONS: These findings confirm the known safety pattern of bDMARDs, including both tumour necrosis factor-α inhibitor (TNFi) and non-TNFi, for the treatment of RA.
引用
- Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28298374. doi:10.1136/annrheumdis-2016-210708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。